Genetically engineered piriformospora indica for fusarium TR4 control and crop growth promotion

Overview

Fusarium wilt caused by Fusarium Tropical Race 4 (TR4) is a devastating soil-borne disease with no effective fungicide or cure currently available. This solution proposes a genetically engineered endophytic fungus, Piriformospora indica, designed to control Fusarium TR4 in soil while simultaneously acting as a biofertilizer to enhance crop productivity. The approach uses a dual-attack strategy combining an antifungal protein (WFhb1-1) and RNA interference molecules targeting key Fusarium genes.

Technical specifications

Core innovation:

• Genetic modification of P. indica with the WFhb1-1 gene for antifungal activity
• Co-expression of dsRNA molecules targeting FRP1 and OPR genes in Fusarium to suppress pathogenicity at the mRNA level
• P. indica is a root-colonizing fungus that induces local and systemic resistance to fungal diseases and tolerance to abiotic stress
• Compatible with vermicompost formulations (1:1 ratio) demonstrated to enhance tomato plant productivity by 40–50%

Key advantages:

• Addresses a disease with no existing effective chemical control
• Functions as both a biocontrol agent and a biofertilizer
• Can be bulk-produced cost-effectively for commercial use
• Builds on prior validated work with P. indica and azotobacter for nutrient uptake and root promotion

Technology readiness level

The technology is currently at early-stage development. Proof-of-concept work has established genetic transformation protocols using a gene gun with GFP reporter validation and hygromycin selection. Prior studies have demonstrated P. indica interactions with azotobacter and algae, as well as biofertilizer efficacy in tomato. Next validation steps include in vitro testing of WFhb1-1 protein expression against Fusarium and confirming dsRNA-mediated gene silencing. Successful results will progress to soil-level trials on crop plants, with plans to evaluate up to ten different control approaches annually. The most robust synthetic strain will be submitted to a funding agency for bulk production and protocol optimization.